These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18853832)

  • 1. Does a delay in performing an activated clotting (ACT) test really matter? A study in nonheparinized blood and a single ACT machine.
    Philip BM; Brock-Utne JG; Lemmens HJ; Jaffe RA; Shuttleworth PE
    J Extra Corpor Technol; 2008 Sep; 40(3):193-5. PubMed ID: 18853832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of point-of-care activated clotting time systems utilized in a single pediatric institution.
    Ojito JW; Hannan RL; Burgos MM; Lim H; Huynh M; Velis E; Arocha M; Tirotta CF; Burke RP
    J Extra Corpor Technol; 2012 Mar; 44(1):15-20. PubMed ID: 22730859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin sensitivity test for patients requiring cardiopulmonary bypass.
    DeBois WJ; Liu J; Elmer B; Ebrahimi H; Voevidko L; Lee LY; Krieger KH; Isom WW; Girardi LN
    J Extra Corpor Technol; 2006 Dec; 38(4):307-9. PubMed ID: 17312901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of activated coagulation time in children: evaluation of the blood-saving kaolin i-STAT activated coagulation time technique in pediatric cardiac anesthesia.
    Ulmer FF; Baulig W; Béttex D; Spielmann N; Bürki C; Weiss M
    J Cardiothorac Vasc Anesth; 2011 Jun; 25(3):395-401. PubMed ID: 21376632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
    Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients.
    Kim H; Szlam F; Tanaka KA; van de Locht A; Ogawa S; Levy JH
    Anesth Analg; 2012 Aug; 115(2):244-52. PubMed ID: 22584552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ACT point-of-care measurements: repeatability and agreement.
    Bosch YP; Ganushchak YM; de Jong DS
    Perfusion; 2006 Jan; 21(1):27-31. PubMed ID: 16485696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new device for in vitro evaluation of thrombogenicity.
    Lermusiaux P; How TV; Black RA
    Med Eng Phys; 2006 May; 28(4):389-93. PubMed ID: 16185909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kaolin-based activated coagulation time measured by sonoclot in patients undergoing cardiopulmonary bypass.
    Ganter MT; Monn A; Tavakoli R; Klaghofer R; Zollinger A; Hofer CK
    J Cardiothorac Vasc Anesth; 2007 Aug; 21(4):524-8. PubMed ID: 17678778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to letter "Evaluations of activated clotting time technologies require understanding activating clotting time system differences" by Marcia L. Zucker.
    Hannan RL; Ojito JW
    J Extra Corpor Technol; 2013 Mar; 45(1):60. PubMed ID: 23691788
    [No Abstract]   [Full Text] [Related]  

  • 12. Activated clotting time (ACT) monitoring of intraoperative heparinization in peripheral vascular surgery.
    Mabry CD; Thompson BW; Read RC
    Am J Surg; 1979 Dec; 138(6):894-900. PubMed ID: 507308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluations of activated clotting time technologies require understanding activating clotting time system differences.
    Zucker ML
    J Extra Corpor Technol; 2013 Mar; 45(1):58-9. PubMed ID: 23691787
    [No Abstract]   [Full Text] [Related]  

  • 14. A change in anticoagulation monitoring improves safety, reduces transfusion, and reduces costs in infants on cardiopulmonary bypass.
    Machovec KA; Jooste EH; Walczak RJ; Homi HM; Jaquiss RD; Lodge AJ; Ames WA
    Paediatr Anaesth; 2015 Jun; 25(6):580-6. PubMed ID: 25530420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the ACT two minutes after heparin injection reliable?
    Bellaiche AL; Nielsen PF; Kirkegaard H
    Perfusion; 2011 Jul; 26(4):322-6. PubMed ID: 21558299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of New Heparin Potency on Activated Clotting Time during Pediatric Cardiac Surgery: A Retrospective Chart Review.
    Thompson K; Alred J; Deyo A; Sievert AN; Sistino JJ
    J Extra Corpor Technol; 2014 Sep; 46(3):224-8. PubMed ID: 26357788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between heparin level and activated clotting time in the adult cardiac surgery population.
    Fitzgerald DJ; Patel A; Body SC; Garvin S
    Perfusion; 2009 Mar; 24(2):93-6. PubMed ID: 19654150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated clotting time monitoring of intraoperative heparinization: our experience and comparison of two techniques.
    Mabry CD; Thompson BW; Read RC; Campbell GS
    Surgery; 1981 Nov; 90(5):889-95. PubMed ID: 7302842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in heparin potency and effects on the activated clotting time in children undergoing cardiopulmonary bypass.
    Guzzetta NA; Amin SJ; Tosone AK; Miller BE
    Anesth Analg; 2012 Oct; 115(4):921-4. PubMed ID: 22822188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole blood coagulation analyzers.
    Health Devices; 1997 Aug; 26(8):296-332. PubMed ID: 9283920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.